The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has given a positive recommendation for the extension of the marketing authorisation for idecabtagene vicleucel (ide-cel), a CAR-T treatment marketed…

The European Commission has granted conditional marketing authorisation for elranatamab, also known as Elrexfio® marketed by the pharmaceutical company Pfizer. This follows an earlier positive recommendation from the European Medicines Agency (EMA – the EU…

MPE and our community are extremely saddened by the ongoing and devastating events in Israel and Gaza. The death of hundreds of innocent people is completely unacceptable, and our deepest sympathy goes out to everyone…

On September 15, 2023, the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has recommended non-renewal of marketing authorisation for belamaf mafadotin (Blenrep®).   Blenrep is currently approved for…

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has granted a positive opinion on the application for an extended marketing authorisation (i.e. a license) for melphalan flufenamide (Pepaxti),…